Get the Stockscreener App
19.83
1.64%
0.32
After Hours:
20.00
0.17
+0.86%
Kodiak Sciences Inc stock is traded at $19.83, with a volume of 1.09M.
It is up +1.64% in the last 24 hours and up +40.64% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$19.51
Open:
$19.37
24h Volume:
1.09M
Relative Volume:
1.23
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-5.2739
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
+7.25%
1M Performance:
+40.64%
6M Performance:
+466.57%
1Y Performance:
+258.59%
1-Day Range:
$18.44
$22.14
1-Week Range:
$18.05
$22.14
52-Week Range:
$1.92
$22.14
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
19.83 | 1.03B | 0 | -197.68M | -158.88M | -3.76 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak Sciences : Jefferies Global Healthcare Conference London November 2025 - MarketScreener
Kodiak Sciences stock hits 52-week high at 21.18 USD - Investing.com India
Kodiak Sciences stock hits 52-week high at 21.18 USD By Investing.com - Investing.com Australia
KOD Maintains Neutral Rating by Chardan Capital | KOD Stock News - GuruFocus
Kodiak Sciences stock price target raised to $26 from $24 at H.C. Wainwright - Investing.com India
KOD: HC Wainwright Maintains Buy Rating, Raises Price Target to $26 | KOD Stock News - GuruFocus
Is Kodiak Sciences Inc. (K27) stock testing key supportCEO Change & AI Enhanced Market Trend Forecasts - newser.com
How to manage a losing position in Kodiak Sciences Inc.Market Risk Summary & Safe Swing Trade Setup Alerts - newser.com
What indicators show strength in Kodiak Sciences Inc.Volume Spike & Expert Curated Trade Setups - newser.com
Does Kodiak Sciences Inc. show high probability of reboundWeekly Risk Report & Weekly Top Gainers Trade List - newser.com
Published on: 2025-11-16 06:53:16 - newser.com
How analysts revise price targets for Kodiak Sciences Inc. (K27) stockJuly 2025 Setups & Free Weekly Chart Analysis and Trade Guides - newser.com
Can technical indicators confirm Kodiak Sciences Inc.’s reversalIPO Watch & Consistent Growth Stock Picks - newser.com
Is Kodiak Sciences Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Proven Capital Preservation Methods - newser.com
Will Kodiak Sciences Inc. stock deliver consistent dividendsTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
What candlestick patterns are forming on Kodiak Sciences Inc.Weekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus - sharewise.com
Decoding Kodiak Sciences Inc (KOD): A Strategic SWOT Insight - GuruFocus
Should I hold or sell Kodiak Sciences Inc. stock in 2025Price Action & Growth Focused Investment Plans - newser.com
Best data tools to analyze Kodiak Sciences Inc. stockRate Hike & Scalable Portfolio Growth Ideas - newser.com
How Kodiak Sciences Inc. stock reacts to Fed rate cutsQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Resistance Check: Why Kodiak Sciences Inc. (K27) stock is a strong analyst pickMarket Risk Analysis & Reliable Price Breakout Alerts - Fundação Cultural do Pará
Chart based exit strategy for Kodiak Sciences Inc.July 2025 Sector Moves & Safe Swing Trade Setups - newser.com
Kodiak Sciences Faces Financial Challenges Amid R&D Focus - TipRanks
Kodiak Sciences (KOD) Anticipates Significant Milestones in 2026 - GuruFocus
Kodiak Sciences (NASDAQ: KOD) posts $72M cash in Q3; late-stage programs advance - Stock Titan
Why Kodiak Sciences (KOD) Is Up 13.6% After Rapid Efficacy Seen in Uveitic Macular Edema Trial - Yahoo Finance
Kodiak Sciences to Present at Upcoming Investor Conferences - 富途牛牛
A Look at Kodiak Sciences's Valuation Following Promising Phase 3 Clinical Trial Results - Yahoo Finance
HC Wainwright & Co. Upgrades Kodiak Sciences (KOD) - Nasdaq
H.C. Wainwright upgrades Kodiak Sciences stock rating to Buy on positive trial data - Investing.com Nigeria
KOD Receives Significant Upgrade from HC Wainwright & Co. | KOD Stock News - GuruFocus
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):